6	ERWINAZE.xml:S1:4:1	O
ADVERSE	ERWINAZE.xml:S1:6:7	O
REACTIONS	ERWINAZE.xml:S1:14:9	O

The	ERWINAZE.xml:S1:27:3	O
following	ERWINAZE.xml:S1:31:9	O
serious	ERWINAZE.xml:S1:41:7	O
adverse	ERWINAZE.xml:S1:49:7	O
reactions	ERWINAZE.xml:S1:57:9	O
are	ERWINAZE.xml:S1:67:3	O
discussed	ERWINAZE.xml:S1:71:9	O
in	ERWINAZE.xml:S1:81:2	O
greater	ERWINAZE.xml:S1:84:7	O
detail	ERWINAZE.xml:S1:92:6	O
in	ERWINAZE.xml:S1:99:2	O
other	ERWINAZE.xml:S1:102:5	O
sections	ERWINAZE.xml:S1:108:8	O
of	ERWINAZE.xml:S1:117:2	O
the	ERWINAZE.xml:S1:120:3	O
label	ERWINAZE.xml:S1:124:5	O
:	ERWINAZE.xml:S1:129:1	O

Hypersensitivity	ERWINAZE.xml:S1:140:16	B-AdverseReaction
reactions	ERWINAZE.xml:S1:157:9	I-AdverseReaction
[	ERWINAZE.xml:S1:167:1	O
see	ERWINAZE.xml:S1:169:3	O
Warnings	ERWINAZE.xml:S1:173:8	O
and	ERWINAZE.xml:S1:182:3	O
Precautions	ERWINAZE.xml:S1:186:11	O
(	ERWINAZE.xml:S1:198:1	O
5.1	ERWINAZE.xml:S1:199:3	O
)	ERWINAZE.xml:S1:202:1	O
]	ERWINAZE.xml:S1:204:1	O

Pancreatitis	ERWINAZE.xml:S1:213:12	B-AdverseReaction
[	ERWINAZE.xml:S1:226:1	O
see	ERWINAZE.xml:S1:228:3	O
Warnings	ERWINAZE.xml:S1:232:8	O
and	ERWINAZE.xml:S1:241:3	O
Precautions	ERWINAZE.xml:S1:245:11	O
(	ERWINAZE.xml:S1:257:1	O
5.2	ERWINAZE.xml:S1:258:3	O
)	ERWINAZE.xml:S1:261:1	O
]	ERWINAZE.xml:S1:263:1	O

Glucose	ERWINAZE.xml:S1:272:7	B-AdverseReaction
intolerance	ERWINAZE.xml:S1:280:11	I-AdverseReaction
[	ERWINAZE.xml:S1:292:1	O
see	ERWINAZE.xml:S1:294:3	O
Warnings	ERWINAZE.xml:S1:298:8	O
and	ERWINAZE.xml:S1:307:3	O
Precautions	ERWINAZE.xml:S1:311:11	O
(	ERWINAZE.xml:S1:323:1	O
5.3	ERWINAZE.xml:S1:324:3	O
)	ERWINAZE.xml:S1:327:1	O
]	ERWINAZE.xml:S1:329:1	O

Thrombosis	ERWINAZE.xml:S1:338:10	B-AdverseReaction
and	ERWINAZE.xml:S1:349:3	O
hemorrhage	ERWINAZE.xml:S1:353:10	B-AdverseReaction
[	ERWINAZE.xml:S1:364:1	O
see	ERWINAZE.xml:S1:366:3	O
Warnings	ERWINAZE.xml:S1:370:8	O
and	ERWINAZE.xml:S1:379:3	O
Precautions	ERWINAZE.xml:S1:383:11	O
(	ERWINAZE.xml:S1:395:1	O
5.4	ERWINAZE.xml:S1:396:3	O
)	ERWINAZE.xml:S1:399:1	O
]	ERWINAZE.xml:S1:401:1	O

The	ERWINAZE.xml:S1:408:3	O
most	ERWINAZE.xml:S1:412:4	O
common	ERWINAZE.xml:S1:417:6	O
adverse	ERWINAZE.xml:S1:424:7	O
reactions	ERWINAZE.xml:S1:432:9	O
(	ERWINAZE.xml:S1:442:1	O
incidence	ERWINAZE.xml:S1:443:9	O
1%	ERWINAZE.xml:S1:453:2	O
or	ERWINAZE.xml:S1:456:2	O
greater	ERWINAZE.xml:S1:459:7	O
)	ERWINAZE.xml:S1:466:1	O
with	ERWINAZE.xml:S1:468:4	O
ERWINAZE	ERWINAZE.xml:S1:473:8	O
treatment	ERWINAZE.xml:S1:482:9	O
are	ERWINAZE.xml:S1:492:3	O
systemic	ERWINAZE.xml:S1:496:8	B-AdverseReaction
hypersensitivity	ERWINAZE.xml:S1:505:16	I-AdverseReaction
,	ERWINAZE.xml:S1:521:1	O
hyperglycemia	ERWINAZE.xml:S1:523:13	B-AdverseReaction
,	ERWINAZE.xml:S1:536:1	O
transaminases	ERWINAZE.xml:S1:538:13	B-AdverseReaction
abnormal	ERWINAZE.xml:S1:552:8	I-AdverseReaction
,	ERWINAZE.xml:S1:560:1	O
fever	ERWINAZE.xml:S1:562:5	B-AdverseReaction
,	ERWINAZE.xml:S1:567:1	O
pancreatitis	ERWINAZE.xml:S1:569:12	B-AdverseReaction
,	ERWINAZE.xml:S1:581:1	O
local	ERWINAZE.xml:S1:583:5	B-AdverseReaction
reactions	ERWINAZE.xml:S1:589:9	I-AdverseReaction
,	ERWINAZE.xml:S1:598:1	O
vomiting	ERWINAZE.xml:S1:600:8	B-AdverseReaction
,	ERWINAZE.xml:S1:608:1	O
nausea	ERWINAZE.xml:S1:610:6	B-AdverseReaction
,	ERWINAZE.xml:S1:616:1	O
thrombosis	ERWINAZE.xml:S1:618:10	B-AdverseReaction
,	ERWINAZE.xml:S1:628:1	O
hyperbilirubinemia	ERWINAZE.xml:S1:630:18	B-AdverseReaction
,	ERWINAZE.xml:S1:648:1	O
abdominal	ERWINAZE.xml:S1:650:9	B-AdverseReaction
pain	ERWINAZE.xml:S1:660:4	I-AdverseReaction
discomfort	ERWINAZE.xml:S1:665:10	I-AdverseReaction
,	ERWINAZE.xml:S1:675:1	O
and	ERWINAZE.xml:S1:677:3	O
diarrhea	ERWINAZE.xml:S1:681:8	B-AdverseReaction
.	ERWINAZE.xml:S1:689:1	O

EXCERPT	ERWINAZE.xml:S1:697:7	O

:	ERWINAZE.xml:S1:704:1	O
Most	ERWINAZE.xml:S1:708:4	O
common	ERWINAZE.xml:S1:713:6	O
adverse	ERWINAZE.xml:S1:720:7	O
reactions	ERWINAZE.xml:S1:728:9	O
(	ERWINAZE.xml:S1:738:1	O
incidence	ERWINAZE.xml:S1:739:9	O
1%	ERWINAZE.xml:S1:749:2	O
or	ERWINAZE.xml:S1:752:2	O
greater	ERWINAZE.xml:S1:755:7	O
)	ERWINAZE.xml:S1:762:1	O
are	ERWINAZE.xml:S1:764:3	O
:	ERWINAZE.xml:S1:767:1	O
systemic	ERWINAZE.xml:S1:769:8	B-AdverseReaction
hypersensitivity	ERWINAZE.xml:S1:778:16	I-AdverseReaction
,	ERWINAZE.xml:S1:794:1	O
hyperglycemia	ERWINAZE.xml:S1:796:13	B-AdverseReaction
,	ERWINAZE.xml:S1:809:1	O
transaminases	ERWINAZE.xml:S1:811:13	B-AdverseReaction
abnormal	ERWINAZE.xml:S1:825:8	I-AdverseReaction
,	ERWINAZE.xml:S1:833:1	O
fever	ERWINAZE.xml:S1:835:5	B-AdverseReaction
,	ERWINAZE.xml:S1:840:1	O
pancreatitis	ERWINAZE.xml:S1:842:12	B-AdverseReaction
,	ERWINAZE.xml:S1:854:1	O
local	ERWINAZE.xml:S1:856:5	B-AdverseReaction
reactions	ERWINAZE.xml:S1:862:9	I-AdverseReaction
,	ERWINAZE.xml:S1:871:1	O
vomiting	ERWINAZE.xml:S1:873:8	B-AdverseReaction
,	ERWINAZE.xml:S1:881:1	O
nausea	ERWINAZE.xml:S1:883:6	B-AdverseReaction
,	ERWINAZE.xml:S1:889:1	O
thrombosis	ERWINAZE.xml:S1:891:10	B-AdverseReaction
,	ERWINAZE.xml:S1:901:1	O
hyperbilirubinemia	ERWINAZE.xml:S1:903:18	B-AdverseReaction
,	ERWINAZE.xml:S1:921:1	O
abdominal	ERWINAZE.xml:S1:923:9	B-AdverseReaction
pain	ERWINAZE.xml:S1:933:4	I-AdverseReaction
discomfort	ERWINAZE.xml:S1:938:10	I-AdverseReaction
,	ERWINAZE.xml:S1:948:1	O
and	ERWINAZE.xml:S1:950:3	O
diarrhea	ERWINAZE.xml:S1:954:8	B-AdverseReaction
.	ERWINAZE.xml:S1:962:1	O

To	ERWINAZE.xml:S1:965:2	O
report	ERWINAZE.xml:S1:968:6	O
SUSPECTED	ERWINAZE.xml:S1:975:9	O
ADVERSE	ERWINAZE.xml:S1:985:7	O
REACTIONS	ERWINAZE.xml:S1:993:9	O
,	ERWINAZE.xml:S1:1002:1	O
contact	ERWINAZE.xml:S1:1004:7	O
Jazz	ERWINAZE.xml:S1:1012:4	O
Pharmaceuticals	ERWINAZE.xml:S1:1017:15	O
,	ERWINAZE.xml:S1:1032:1	O
Inc	ERWINAZE.xml:S1:1034:3	O
.	ERWINAZE.xml:S1:1037:1	O

at	ERWINAZE.xml:S1:1039:2	O
1	ERWINAZE.xml:S1:1042:1	O
-	ERWINAZE.xml:S1:1043:1	O
800	ERWINAZE.xml:S1:1044:3	O
-	ERWINAZE.xml:S1:1047:1	O
520	ERWINAZE.xml:S1:1048:3	O
-	ERWINAZE.xml:S1:1051:1	O
5568	ERWINAZE.xml:S1:1052:4	O
or	ERWINAZE.xml:S1:1057:2	O
FDA	ERWINAZE.xml:S1:1060:3	O
at	ERWINAZE.xml:S1:1064:2	O
1	ERWINAZE.xml:S1:1067:1	O
-	ERWINAZE.xml:S1:1068:1	O
800	ERWINAZE.xml:S1:1069:3	O
-	ERWINAZE.xml:S1:1072:1	O
FDA	ERWINAZE.xml:S1:1073:3	O
-	ERWINAZE.xml:S1:1076:1	O
1088	ERWINAZE.xml:S1:1077:4	O
or	ERWINAZE.xml:S1:1082:2	O
www	ERWINAZE.xml:S1:1088:3	O
.	ERWINAZE.xml:S1:1091:1	O
fda	ERWINAZE.xml:S1:1092:3	O
.	ERWINAZE.xml:S1:1095:1	O
gov	ERWINAZE.xml:S1:1096:3	O
medwatch	ERWINAZE.xml:S1:1100:8	O

6.1	ERWINAZE.xml:S1:1123:3	O

Clinical	ERWINAZE.xml:S1:1127:8	O
Studies	ERWINAZE.xml:S1:1136:7	O

Because	ERWINAZE.xml:S1:1147:7	O
clinical	ERWINAZE.xml:S1:1155:8	O
trials	ERWINAZE.xml:S1:1164:6	O
are	ERWINAZE.xml:S1:1171:3	O
conducted	ERWINAZE.xml:S1:1175:9	O
under	ERWINAZE.xml:S1:1185:5	O
controlled	ERWINAZE.xml:S1:1191:10	O
,	ERWINAZE.xml:S1:1201:1	O
but	ERWINAZE.xml:S1:1203:3	O
widely	ERWINAZE.xml:S1:1207:6	O
varying	ERWINAZE.xml:S1:1214:7	O
conditions	ERWINAZE.xml:S1:1222:10	O
,	ERWINAZE.xml:S1:1232:1	O
adverse	ERWINAZE.xml:S1:1234:7	O
reaction	ERWINAZE.xml:S1:1242:8	O
rates	ERWINAZE.xml:S1:1251:5	O
observed	ERWINAZE.xml:S1:1257:8	O
in	ERWINAZE.xml:S1:1266:2	O
clinical	ERWINAZE.xml:S1:1269:8	O
trials	ERWINAZE.xml:S1:1278:6	O
of	ERWINAZE.xml:S1:1285:2	O
ERWINAZE	ERWINAZE.xml:S1:1288:8	O
cannot	ERWINAZE.xml:S1:1297:6	O
be	ERWINAZE.xml:S1:1304:2	O
directly	ERWINAZE.xml:S1:1307:8	O
compared	ERWINAZE.xml:S1:1316:8	O
to	ERWINAZE.xml:S1:1325:2	O
rates	ERWINAZE.xml:S1:1328:5	O
in	ERWINAZE.xml:S1:1334:2	O
the	ERWINAZE.xml:S1:1337:3	O
clinical	ERWINAZE.xml:S1:1341:8	O
trials	ERWINAZE.xml:S1:1350:6	O
of	ERWINAZE.xml:S1:1357:2	O
other	ERWINAZE.xml:S1:1360:5	O
drugs	ERWINAZE.xml:S1:1366:5	O
and	ERWINAZE.xml:S1:1372:3	O
may	ERWINAZE.xml:S1:1376:3	O
not	ERWINAZE.xml:S1:1380:3	O
reflect	ERWINAZE.xml:S1:1384:7	O
the	ERWINAZE.xml:S1:1392:3	O
rates	ERWINAZE.xml:S1:1396:5	O
observed	ERWINAZE.xml:S1:1402:8	O
in	ERWINAZE.xml:S1:1411:2	O
practice	ERWINAZE.xml:S1:1414:8	O
.	ERWINAZE.xml:S1:1422:1	O

The	ERWINAZE.xml:S1:1428:3	O
data	ERWINAZE.xml:S1:1432:4	O
presented	ERWINAZE.xml:S1:1437:9	O
below	ERWINAZE.xml:S1:1447:5	O
are	ERWINAZE.xml:S1:1453:3	O
based	ERWINAZE.xml:S1:1457:5	O
on	ERWINAZE.xml:S1:1463:2	O
information	ERWINAZE.xml:S1:1466:11	O
collected	ERWINAZE.xml:S1:1478:9	O
from	ERWINAZE.xml:S1:1488:4	O
Study	ERWINAZE.xml:S1:1493:5	O
1	ERWINAZE.xml:S1:1499:1	O
,	ERWINAZE.xml:S1:1500:1	O
a	ERWINAZE.xml:S1:1502:1	O
single	ERWINAZE.xml:S1:1504:6	O
-	ERWINAZE.xml:S1:1510:1	O
arm	ERWINAZE.xml:S1:1511:3	O
,	ERWINAZE.xml:S1:1514:1	O
multi	ERWINAZE.xml:S1:1516:5	O
-	ERWINAZE.xml:S1:1521:1	O
center	ERWINAZE.xml:S1:1522:6	O
,	ERWINAZE.xml:S1:1528:1	O
open	ERWINAZE.xml:S1:1530:4	O
-	ERWINAZE.xml:S1:1534:1	O
label	ERWINAZE.xml:S1:1535:5	O
,	ERWINAZE.xml:S1:1540:1	O
safety	ERWINAZE.xml:S1:1542:6	O
and	ERWINAZE.xml:S1:1549:3	O
clinical	ERWINAZE.xml:S1:1553:8	O
pharmacology	ERWINAZE.xml:S1:1562:12	O
trial	ERWINAZE.xml:S1:1575:5	O
(	ERWINAZE.xml:S1:1581:1	O
intramuscular	ERWINAZE.xml:S1:1582:13	O
administration	ERWINAZE.xml:S1:1596:14	O
)	ERWINAZE.xml:S1:1610:1	O
,	ERWINAZE.xml:S1:1611:1	O
the	ERWINAZE.xml:S1:1613:3	O
ERWINAZE	ERWINAZE.xml:S1:1617:8	O
Master	ERWINAZE.xml:S1:1626:6	O
Treatment	ERWINAZE.xml:S1:1633:9	O
Protocol	ERWINAZE.xml:S1:1643:8	O
(	ERWINAZE.xml:S1:1652:1	O
EMTP	ERWINAZE.xml:S1:1653:4	O
)	ERWINAZE.xml:S1:1657:1	O
,	ERWINAZE.xml:S1:1658:1	O
an	ERWINAZE.xml:S1:1660:2	O
expanded	ERWINAZE.xml:S1:1663:8	O
access	ERWINAZE.xml:S1:1672:6	O
program	ERWINAZE.xml:S1:1679:7	O
(	ERWINAZE.xml:S1:1687:1	O
both	ERWINAZE.xml:S1:1688:4	O
intramuscular	ERWINAZE.xml:S1:1693:13	O
,	ERWINAZE.xml:S1:1706:1	O
intravenous	ERWINAZE.xml:S1:1708:11	O
,	ERWINAZE.xml:S1:1719:1	O
and	ERWINAZE.xml:S1:1721:3	O
other	ERWINAZE.xml:S1:1725:5	O
or	ERWINAZE.xml:S1:1731:2	O
unknown	ERWINAZE.xml:S1:1734:7	O
administration	ERWINAZE.xml:S1:1742:14	O
)	ERWINAZE.xml:S1:1756:1	O
,	ERWINAZE.xml:S1:1757:1	O
and	ERWINAZE.xml:S1:1759:3	O
Study	ERWINAZE.xml:S1:1763:5	O
2	ERWINAZE.xml:S1:1769:1	O
,	ERWINAZE.xml:S1:1770:1	O
a	ERWINAZE.xml:S1:1772:1	O
single	ERWINAZE.xml:S1:1774:6	O
-	ERWINAZE.xml:S1:1780:1	O
arm	ERWINAZE.xml:S1:1781:3	O
,	ERWINAZE.xml:S1:1784:1	O
multi	ERWINAZE.xml:S1:1786:5	O
-	ERWINAZE.xml:S1:1791:1	O
center	ERWINAZE.xml:S1:1792:6	O
,	ERWINAZE.xml:S1:1798:1	O
open	ERWINAZE.xml:S1:1800:4	O
-	ERWINAZE.xml:S1:1804:1	O
label	ERWINAZE.xml:S1:1805:5	O
,	ERWINAZE.xml:S1:1810:1	O
pharmacokinetic	ERWINAZE.xml:S1:1812:15	O
(	ERWINAZE.xml:S1:1828:1	O
PK	ERWINAZE.xml:S1:1829:2	O
)	ERWINAZE.xml:S1:1831:1	O
study	ERWINAZE.xml:S1:1833:5	O
trial	ERWINAZE.xml:S1:1839:5	O
of	ERWINAZE.xml:S1:1845:2	O
intravenous	ERWINAZE.xml:S1:1848:11	O
administration	ERWINAZE.xml:S1:1860:14	O
of	ERWINAZE.xml:S1:1875:2	O
ERWINAZE	ERWINAZE.xml:S1:1878:8	O
.	ERWINAZE.xml:S1:1886:1	O
Study	ERWINAZE.xml:S1:1887:5	O
1	ERWINAZE.xml:S1:1893:1	O
enrolled	ERWINAZE.xml:S1:1895:8	O
58	ERWINAZE.xml:S1:1904:2	O
patients	ERWINAZE.xml:S1:1907:8	O
treated	ERWINAZE.xml:S1:1916:7	O
on	ERWINAZE.xml:S1:1924:2	O
National	ERWINAZE.xml:S1:1927:8	O
Cancer	ERWINAZE.xml:S1:1936:6	O
Institute	ERWINAZE.xml:S1:1943:9	O
(	ERWINAZE.xml:S1:1953:1	O
NCI	ERWINAZE.xml:S1:1954:3	O
)-	ERWINAZE.xml:S1:1957:2	O
sponsored	ERWINAZE.xml:S1:1959:9	O
cooperative	ERWINAZE.xml:S1:1969:11	O
group	ERWINAZE.xml:S1:1981:5	O
ALL	ERWINAZE.xml:S1:1987:3	O
protocols	ERWINAZE.xml:S1:1991:9	O
who	ERWINAZE.xml:S1:2001:3	O
were	ERWINAZE.xml:S1:2005:4	O
unable	ERWINAZE.xml:S1:2010:6	O
to	ERWINAZE.xml:S1:2017:2	O
continue	ERWINAZE.xml:S1:2020:8	O
to	ERWINAZE.xml:S1:2029:2	O
receive	ERWINAZE.xml:S1:2032:7	O
pegaspargase	ERWINAZE.xml:S1:2040:12	O
due	ERWINAZE.xml:S1:2053:3	O
to	ERWINAZE.xml:S1:2057:2	O
hypersensitivity	ERWINAZE.xml:S1:2060:16	O
reactions	ERWINAZE.xml:S1:2077:9	O
.	ERWINAZE.xml:S1:2086:1	O

Patients	ERWINAZE.xml:S1:2088:8	O
received	ERWINAZE.xml:S1:2097:8	O
6	ERWINAZE.xml:S1:2106:1	O
doses	ERWINAZE.xml:S1:2108:5	O
of	ERWINAZE.xml:S1:2114:2	O
ERWINAZE	ERWINAZE.xml:S1:2117:8	O
25	ERWINAZE.xml:S1:2126:2	O
,	ERWINAZE.xml:S1:2128:1	O
000	ERWINAZE.xml:S1:2129:3	O
International	ERWINAZE.xml:S1:2133:13	O
Units	ERWINAZE.xml:S1:2147:5	O
m	ERWINAZE.xml:S1:2153:1	O
2	ERWINAZE.xml:S1:2156:1	O
intramuscularly	ERWINAZE.xml:S1:2159:15	O
on	ERWINAZE.xml:S1:2175:2	O
a	ERWINAZE.xml:S1:2178:1	O
Monday	ERWINAZE.xml:S1:2180:6	O
,	ERWINAZE.xml:S1:2186:1	O
Wednesday	ERWINAZE.xml:S1:2188:9	O
,	ERWINAZE.xml:S1:2197:1	O
and	ERWINAZE.xml:S1:2199:3	O
Friday	ERWINAZE.xml:S1:2203:6	O
schedule	ERWINAZE.xml:S1:2210:8	O
as	ERWINAZE.xml:S1:2219:2	O
a	ERWINAZE.xml:S1:2222:1	O
replacement	ERWINAZE.xml:S1:2224:11	O
for	ERWINAZE.xml:S1:2236:3	O
each	ERWINAZE.xml:S1:2240:4	O
scheduled	ERWINAZE.xml:S1:2245:9	O
dose	ERWINAZE.xml:S1:2255:4	O
of	ERWINAZE.xml:S1:2260:2	O
pegaspargase	ERWINAZE.xml:S1:2263:12	O
remaining	ERWINAZE.xml:S1:2276:9	O
on	ERWINAZE.xml:S1:2286:2	O
their	ERWINAZE.xml:S1:2289:5	O
original	ERWINAZE.xml:S1:2295:8	O
treatment	ERWINAZE.xml:S1:2304:9	O
protocol	ERWINAZE.xml:S1:2314:8	O
.	ERWINAZE.xml:S1:2322:1	O

The	ERWINAZE.xml:S1:2324:3	O
Study	ERWINAZE.xml:S1:2328:5	O
1	ERWINAZE.xml:S1:2334:1	O
population	ERWINAZE.xml:S1:2336:10	O
included	ERWINAZE.xml:S1:2347:8	O
patients	ERWINAZE.xml:S1:2356:8	O
with	ERWINAZE.xml:S1:2365:4	O
a	ERWINAZE.xml:S1:2370:1	O
median	ERWINAZE.xml:S1:2372:6	O
age	ERWINAZE.xml:S1:2379:3	O
of	ERWINAZE.xml:S1:2383:2	O
11	ERWINAZE.xml:S1:2386:2	O
years	ERWINAZE.xml:S1:2389:5	O
(	ERWINAZE.xml:S1:2395:1	O
2	ERWINAZE.xml:S1:2396:1	O
to	ERWINAZE.xml:S1:2398:2	O
18	ERWINAZE.xml:S1:2401:2	O
years	ERWINAZE.xml:S1:2404:5	O
)	ERWINAZE.xml:S1:2409:1	O
;	ERWINAZE.xml:S1:2410:1	O
59%	ERWINAZE.xml:S1:2412:3	O
were	ERWINAZE.xml:S1:2416:4	O
male	ERWINAZE.xml:S1:2421:4	O
,	ERWINAZE.xml:S1:2425:1	O
78%	ERWINAZE.xml:S1:2427:3	O
were	ERWINAZE.xml:S1:2431:4	O
White	ERWINAZE.xml:S1:2436:5	O
,	ERWINAZE.xml:S1:2441:1	O
10%	ERWINAZE.xml:S1:2443:3	O
were	ERWINAZE.xml:S1:2447:4	O
Black	ERWINAZE.xml:S1:2452:5	O
African	ERWINAZE.xml:S1:2458:7	O
American	ERWINAZE.xml:S1:2466:8	O
,	ERWINAZE.xml:S1:2474:1	O
5%	ERWINAZE.xml:S1:2476:2	O
were	ERWINAZE.xml:S1:2479:4	O
Asian	ERWINAZE.xml:S1:2484:5	O
,	ERWINAZE.xml:S1:2489:1	O
and	ERWINAZE.xml:S1:2491:3	O
7%	ERWINAZE.xml:S1:2495:2	O
were	ERWINAZE.xml:S1:2498:4	O
other	ERWINAZE.xml:S1:2503:5	O
or	ERWINAZE.xml:S1:2509:2	O
unknown	ERWINAZE.xml:S1:2512:7	O
.	ERWINAZE.xml:S1:2519:1	O

A	ERWINAZE.xml:S1:2521:1	O
total	ERWINAZE.xml:S1:2523:5	O
of	ERWINAZE.xml:S1:2529:2	O
35%	ERWINAZE.xml:S1:2532:3	O
were	ERWINAZE.xml:S1:2536:4	O
Hispanic	ERWINAZE.xml:S1:2541:8	O
or	ERWINAZE.xml:S1:2550:2	O
Latino	ERWINAZE.xml:S1:2553:6	O
.	ERWINAZE.xml:S1:2559:1	O

In	ERWINAZE.xml:S1:2561:2	O
Study	ERWINAZE.xml:S1:2564:5	O
1	ERWINAZE.xml:S1:2570:1	O
,	ERWINAZE.xml:S1:2571:1	O
the	ERWINAZE.xml:S1:2573:3	O
number	ERWINAZE.xml:S1:2577:6	O
of	ERWINAZE.xml:S1:2584:2	O
ERWINAZE	ERWINAZE.xml:S1:2587:8	O
courses	ERWINAZE.xml:S1:2596:7	O
ranged	ERWINAZE.xml:S1:2604:6	O
from	ERWINAZE.xml:S1:2611:4	O
1	ERWINAZE.xml:S1:2616:1	O
to	ERWINAZE.xml:S1:2618:2	O
9	ERWINAZE.xml:S1:2621:1	O
.	ERWINAZE.xml:S1:2622:1	O

In	ERWINAZE.xml:S1:2624:2	O
this	ERWINAZE.xml:S1:2627:4	O
study	ERWINAZE.xml:S1:2632:5	O
,	ERWINAZE.xml:S1:2637:1	O
76%	ERWINAZE.xml:S1:2639:3	O
(	ERWINAZE.xml:S1:2643:1	O
44	ERWINAZE.xml:S1:2644:2	O
of	ERWINAZE.xml:S1:2647:2	O
58	ERWINAZE.xml:S1:2650:2	O
)	ERWINAZE.xml:S1:2652:1	O
completed	ERWINAZE.xml:S1:2654:9	O
all	ERWINAZE.xml:S1:2664:3	O
planned	ERWINAZE.xml:S1:2668:7	O
therapy	ERWINAZE.xml:S1:2676:7	O
.	ERWINAZE.xml:S1:2683:1	O

Fourteen	ERWINAZE.xml:S1:2685:8	O
(	ERWINAZE.xml:S1:2694:1	O
24%	ERWINAZE.xml:S1:2695:3	O
)	ERWINAZE.xml:S1:2698:1	O
patients	ERWINAZE.xml:S1:2700:8	O
stopped	ERWINAZE.xml:S1:2709:7	O
therapy	ERWINAZE.xml:S1:2717:7	O
prior	ERWINAZE.xml:S1:2725:5	O
to	ERWINAZE.xml:S1:2731:2	O
completion	ERWINAZE.xml:S1:2734:10	O
;	ERWINAZE.xml:S1:2744:1	O
seven	ERWINAZE.xml:S1:2746:5	O
due	ERWINAZE.xml:S1:2752:3	O
to	ERWINAZE.xml:S1:2756:2	O
allergic	ERWINAZE.xml:S1:2759:8	B-AdverseReaction
reactions	ERWINAZE.xml:S1:2768:9	I-AdverseReaction
,	ERWINAZE.xml:S1:2777:1	O
five	ERWINAZE.xml:S1:2779:4	O
due	ERWINAZE.xml:S1:2784:3	O
to	ERWINAZE.xml:S1:2788:2	O
physician	ERWINAZE.xml:S1:2791:9	O
or	ERWINAZE.xml:S1:2801:2	O
patient	ERWINAZE.xml:S1:2804:7	O
choice	ERWINAZE.xml:S1:2812:6	O
,	ERWINAZE.xml:S1:2818:1	O
one	ERWINAZE.xml:S1:2820:3	O
due	ERWINAZE.xml:S1:2824:3	O
to	ERWINAZE.xml:S1:2828:2	O
disease	ERWINAZE.xml:S1:2831:7	O
progression	ERWINAZE.xml:S1:2839:11	O
,	ERWINAZE.xml:S1:2850:1	O
and	ERWINAZE.xml:S1:2852:3	O
one	ERWINAZE.xml:S1:2856:3	O
due	ERWINAZE.xml:S1:2860:3	O
to	ERWINAZE.xml:S1:2864:2	O
discontinuation	ERWINAZE.xml:S1:2867:15	O
during	ERWINAZE.xml:S1:2883:6	O
frontline	ERWINAZE.xml:S1:2890:9	O
protocol	ERWINAZE.xml:S1:2900:8	O
.	ERWINAZE.xml:S1:2908:1	O

All	ERWINAZE.xml:S1:2910:3	O
other	ERWINAZE.xml:S1:2914:5	O
chemotherapy	ERWINAZE.xml:S1:2920:12	O
was	ERWINAZE.xml:S1:2933:3	O
continued	ERWINAZE.xml:S1:2937:9	O
according	ERWINAZE.xml:S1:2947:9	O
to	ERWINAZE.xml:S1:2957:2	O
the	ERWINAZE.xml:S1:2960:3	O
patient	ERWINAZE.xml:S1:2964:7	O
's	ERWINAZE.xml:S1:2971:2	O
prescribed	ERWINAZE.xml:S1:2974:10	O
treatment	ERWINAZE.xml:S1:2985:9	O
regimen	ERWINAZE.xml:S1:2995:7	O
[	ERWINAZE.xml:S1:3003:1	O
see	ERWINAZE.xml:S1:3006:3	O
Clinical	ERWINAZE.xml:S1:3010:8	O
Studies	ERWINAZE.xml:S1:3019:7	O
(	ERWINAZE.xml:S1:3027:1	O
14	ERWINAZE.xml:S1:3030:2	O
)	ERWINAZE.xml:S1:3034:1	O
]	ERWINAZE.xml:S1:3037:1	O
.	ERWINAZE.xml:S1:3038:1	O
Study	ERWINAZE.xml:S1:3039:5	O
2	ERWINAZE.xml:S1:3045:1	O
enrolled	ERWINAZE.xml:S1:3047:8	O
30	ERWINAZE.xml:S1:3056:2	O
patients	ERWINAZE.xml:S1:3059:8	O
[	ERWINAZE.xml:S1:3068:1	O
29	ERWINAZE.xml:S1:3069:2	O
were	ERWINAZE.xml:S1:3072:4	O
being	ERWINAZE.xml:S1:3077:5	O
treated	ERWINAZE.xml:S1:3083:7	O
for	ERWINAZE.xml:S1:3091:3	O
ALL	ERWINAZE.xml:S1:3095:3	O
and	ERWINAZE.xml:S1:3099:3	O
one	ERWINAZE.xml:S1:3103:3	O
for	ERWINAZE.xml:S1:3107:3	O
lymphoblastic	ERWINAZE.xml:S1:3111:13	O
lymphoma	ERWINAZE.xml:S1:3125:8	O
(	ERWINAZE.xml:S1:3134:1	O
LBL	ERWINAZE.xml:S1:3135:3	O
)]	ERWINAZE.xml:S1:3138:2	O
following	ERWINAZE.xml:S1:3141:9	O
allergy	ERWINAZE.xml:S1:3151:7	O
to	ERWINAZE.xml:S1:3159:2	O
native	ERWINAZE.xml:S1:3162:6	O
E.	ERWINAZE.xml:S1:3170:2	O
coli	ERWINAZE.xml:S1:3173:4	O
asparaginase	ERWINAZE.xml:S1:3179:12	O
or	ERWINAZE.xml:S1:3192:2	O
pegaspargase	ERWINAZE.xml:S1:3195:12	O
.	ERWINAZE.xml:S1:3207:1	O

Patients	ERWINAZE.xml:S1:3209:8	O
received	ERWINAZE.xml:S1:3218:8	O
ERWINAZE	ERWINAZE.xml:S1:3227:8	O
25	ERWINAZE.xml:S1:3236:2	O
,	ERWINAZE.xml:S1:3238:1	O
000	ERWINAZE.xml:S1:3239:3	O
International	ERWINAZE.xml:S1:3243:13	O
Unit	ERWINAZE.xml:S1:3257:4	O
m	ERWINAZE.xml:S1:3262:1	O
2	ERWINAZE.xml:S1:3265:1	O
dose	ERWINAZE.xml:S1:3269:4	O
,	ERWINAZE.xml:S1:3273:1	O
administered	ERWINAZE.xml:S1:3275:12	O
by	ERWINAZE.xml:S1:3288:2	O
intravenous	ERWINAZE.xml:S1:3291:11	O
infusion	ERWINAZE.xml:S1:3303:8	O
on	ERWINAZE.xml:S1:3312:2	O
a	ERWINAZE.xml:S1:3315:1	O
Monday	ERWINAZE.xml:S1:3317:6	O
,	ERWINAZE.xml:S1:3323:1	O
Wednesday	ERWINAZE.xml:S1:3325:9	O
,	ERWINAZE.xml:S1:3334:1	O
and	ERWINAZE.xml:S1:3336:3	O
Friday	ERWINAZE.xml:S1:3340:6	O
schedule	ERWINAZE.xml:S1:3347:8	O
(	ERWINAZE.xml:S1:3356:1	O
6	ERWINAZE.xml:S1:3357:1	O
doses	ERWINAZE.xml:S1:3359:5	O
)	ERWINAZE.xml:S1:3364:1	O
as	ERWINAZE.xml:S1:3366:2	O
a	ERWINAZE.xml:S1:3369:1	O
replacement	ERWINAZE.xml:S1:3371:11	O
for	ERWINAZE.xml:S1:3383:3	O
doses	ERWINAZE.xml:S1:3387:5	O
remaining	ERWINAZE.xml:S1:3393:9	O
on	ERWINAZE.xml:S1:3403:2	O
their	ERWINAZE.xml:S1:3406:5	O
original	ERWINAZE.xml:S1:3412:8	O
treatment	ERWINAZE.xml:S1:3421:9	O
plan	ERWINAZE.xml:S1:3431:4	O
.	ERWINAZE.xml:S1:3435:1	O

The	ERWINAZE.xml:S1:3437:3	O
Study	ERWINAZE.xml:S1:3441:5	O
2	ERWINAZE.xml:S1:3447:1	O
population	ERWINAZE.xml:S1:3449:10	O
included	ERWINAZE.xml:S1:3460:8	O
patients	ERWINAZE.xml:S1:3469:8	O
with	ERWINAZE.xml:S1:3478:4	O
a	ERWINAZE.xml:S1:3483:1	O
median	ERWINAZE.xml:S1:3485:6	O
age	ERWINAZE.xml:S1:3492:3	O
of	ERWINAZE.xml:S1:3496:2	O
7	ERWINAZE.xml:S1:3499:1	O
years	ERWINAZE.xml:S1:3501:5	O
(	ERWINAZE.xml:S1:3507:1	O
1	ERWINAZE.xml:S1:3508:1	O
to	ERWINAZE.xml:S1:3510:2	O
17	ERWINAZE.xml:S1:3513:2	O
years	ERWINAZE.xml:S1:3516:5	O
)	ERWINAZE.xml:S1:3521:1	O
;	ERWINAZE.xml:S1:3522:1	O
63%	ERWINAZE.xml:S1:3524:3	O
were	ERWINAZE.xml:S1:3528:4	O
male	ERWINAZE.xml:S1:3533:4	O
,	ERWINAZE.xml:S1:3537:1	O
27%	ERWINAZE.xml:S1:3539:3	O
were	ERWINAZE.xml:S1:3543:4	O
Hispanic	ERWINAZE.xml:S1:3548:8	O
or	ERWINAZE.xml:S1:3557:2	O
Latino	ERWINAZE.xml:S1:3560:6	O
,	ERWINAZE.xml:S1:3566:1	O
83%	ERWINAZE.xml:S1:3568:3	O
were	ERWINAZE.xml:S1:3572:4	O
White	ERWINAZE.xml:S1:3577:5	O
,	ERWINAZE.xml:S1:3582:1	O
3%	ERWINAZE.xml:S1:3584:2	O
were	ERWINAZE.xml:S1:3587:4	O
Black	ERWINAZE.xml:S1:3592:5	O
African	ERWINAZE.xml:S1:3598:7	O
American	ERWINAZE.xml:S1:3606:8	O
,	ERWINAZE.xml:S1:3614:1	O
7%	ERWINAZE.xml:S1:3616:2	O
were	ERWINAZE.xml:S1:3619:4	O
Asian	ERWINAZE.xml:S1:3624:5	O
,	ERWINAZE.xml:S1:3629:1	O
and	ERWINAZE.xml:S1:3631:3	O
7%	ERWINAZE.xml:S1:3635:2	O
were	ERWINAZE.xml:S1:3638:4	O
other	ERWINAZE.xml:S1:3643:5	O
(	ERWINAZE.xml:S1:3649:1	O
American	ERWINAZE.xml:S1:3650:8	O
Indian	ERWINAZE.xml:S1:3659:6	O
,	ERWINAZE.xml:S1:3665:1	O
Alaska	ERWINAZE.xml:S1:3667:6	O
Native	ERWINAZE.xml:S1:3674:6	O
or	ERWINAZE.xml:S1:3681:2	O
Indian	ERWINAZE.xml:S1:3684:6	O
)	ERWINAZE.xml:S1:3690:1	O
[	ERWINAZE.xml:S1:3692:1	O
see	ERWINAZE.xml:S1:3695:3	O
Clinical	ERWINAZE.xml:S1:3699:8	O
Studies	ERWINAZE.xml:S1:3708:7	O
(	ERWINAZE.xml:S1:3716:1	O
14	ERWINAZE.xml:S1:3717:2	O
)	ERWINAZE.xml:S1:3719:1	O
]	ERWINAZE.xml:S1:3722:1	O
.	ERWINAZE.xml:S1:3723:1	O

The	ERWINAZE.xml:S1:3729:3	O
EMTP	ERWINAZE.xml:S1:3733:4	O
trial	ERWINAZE.xml:S1:3738:5	O
enrolled	ERWINAZE.xml:S1:3744:8	O
1368	ERWINAZE.xml:S1:3753:4	O
patients	ERWINAZE.xml:S1:3758:8	O
with	ERWINAZE.xml:S1:3767:4	O
ALL	ERWINAZE.xml:S1:3772:3	O
or	ERWINAZE.xml:S1:3776:2	O
lymphoblastic	ERWINAZE.xml:S1:3779:13	O
lymphoma	ERWINAZE.xml:S1:3793:8	O
who	ERWINAZE.xml:S1:3802:3	O
received	ERWINAZE.xml:S1:3806:8	O
ERWINAZE	ERWINAZE.xml:S1:3815:8	O
after	ERWINAZE.xml:S1:3824:5	O
developing	ERWINAZE.xml:S1:3830:10	O
systemic	ERWINAZE.xml:S1:3841:8	O
hypersensitivity	ERWINAZE.xml:S1:3850:16	O
to	ERWINAZE.xml:S1:3867:2	O
an	ERWINAZE.xml:S1:3870:2	O
E.	ERWINAZE.xml:S1:3874:2	O
coli	ERWINAZE.xml:S1:3877:4	O
-	ERWINAZE.xml:S1:3883:1	O
derived	ERWINAZE.xml:S1:3884:7	O
asparaginase	ERWINAZE.xml:S1:3892:12	O
.	ERWINAZE.xml:S1:3904:1	O

Of	ERWINAZE.xml:S1:3906:2	O
these	ERWINAZE.xml:S1:3909:5	O
1368	ERWINAZE.xml:S1:3915:4	O
patients	ERWINAZE.xml:S1:3920:8	O
,	ERWINAZE.xml:S1:3928:1	O
safety	ERWINAZE.xml:S1:3930:6	O
data	ERWINAZE.xml:S1:3937:4	O
were	ERWINAZE.xml:S1:3942:4	O
received	ERWINAZE.xml:S1:3947:8	O
for	ERWINAZE.xml:S1:3956:3	O
940	ERWINAZE.xml:S1:3960:3	O
patients	ERWINAZE.xml:S1:3964:8	O
with	ERWINAZE.xml:S1:3973:4	O
a	ERWINAZE.xml:S1:3978:1	O
median	ERWINAZE.xml:S1:3980:6	O
age	ERWINAZE.xml:S1:3987:3	O
of	ERWINAZE.xml:S1:3991:2	O
9	ERWINAZE.xml:S1:3994:1	O
years	ERWINAZE.xml:S1:3996:5	O
(	ERWINAZE.xml:S1:4002:1	O
0	ERWINAZE.xml:S1:4003:1	O
to	ERWINAZE.xml:S1:4005:2	O
76	ERWINAZE.xml:S1:4008:2	O
years	ERWINAZE.xml:S1:4011:5	O
)	ERWINAZE.xml:S1:4016:1	O
,	ERWINAZE.xml:S1:4017:1	O
63%	ERWINAZE.xml:S1:4019:3	O
were	ERWINAZE.xml:S1:4023:4	O
male	ERWINAZE.xml:S1:4028:4	O
,	ERWINAZE.xml:S1:4032:1	O
91%	ERWINAZE.xml:S1:4034:3	O
with	ERWINAZE.xml:S1:4038:4	O
leukemia	ERWINAZE.xml:S1:4043:8	O
,	ERWINAZE.xml:S1:4051:1	O
3%	ERWINAZE.xml:S1:4053:2	O
with	ERWINAZE.xml:S1:4056:4	O
lymphoma	ERWINAZE.xml:S1:4061:8	O
,	ERWINAZE.xml:S1:4069:1	O
and	ERWINAZE.xml:S1:4071:3	O
6%	ERWINAZE.xml:S1:4075:2	O
with	ERWINAZE.xml:S1:4078:4	O
unknown	ERWINAZE.xml:S1:4083:7	O
disease	ERWINAZE.xml:S1:4091:7	O
information	ERWINAZE.xml:S1:4099:11	O
.	ERWINAZE.xml:S1:4110:1	O

Patients	ERWINAZE.xml:S1:4112:8	O
received	ERWINAZE.xml:S1:4121:8	O
ERWINAZE	ERWINAZE.xml:S1:4130:8	O
according	ERWINAZE.xml:S1:4139:9	O
to	ERWINAZE.xml:S1:4149:2	O
several	ERWINAZE.xml:S1:4152:7	O
schedules	ERWINAZE.xml:S1:4160:9	O
,	ERWINAZE.xml:S1:4169:1	O
and	ERWINAZE.xml:S1:4171:3	O
treatment	ERWINAZE.xml:S1:4175:9	O
center	ERWINAZE.xml:S1:4185:6	O
specifications	ERWINAZE.xml:S1:4192:14	O
with	ERWINAZE.xml:S1:4207:4	O
doses	ERWINAZE.xml:S1:4212:5	O
that	ERWINAZE.xml:S1:4218:4	O
ranged	ERWINAZE.xml:S1:4223:6	O
from	ERWINAZE.xml:S1:4230:4	O
20	ERWINAZE.xml:S1:4235:2	O
,	ERWINAZE.xml:S1:4237:1	O
000	ERWINAZE.xml:S1:4238:3	O
to	ERWINAZE.xml:S1:4242:2	O
25	ERWINAZE.xml:S1:4245:2	O
,	ERWINAZE.xml:S1:4247:1	O
000	ERWINAZE.xml:S1:4248:3	O
International	ERWINAZE.xml:S1:4252:13	O
Units	ERWINAZE.xml:S1:4266:5	O
m	ERWINAZE.xml:S1:4272:1	O
2	ERWINAZE.xml:S1:4275:1	O
.	ERWINAZE.xml:S1:4278:1	O

The	ERWINAZE.xml:S1:4280:3	O
route	ERWINAZE.xml:S1:4284:5	O
of	ERWINAZE.xml:S1:4290:2	O
administration	ERWINAZE.xml:S1:4293:14	O
was	ERWINAZE.xml:S1:4308:3	O
intramuscular	ERWINAZE.xml:S1:4312:13	O
n	ERWINAZE.xml:S1:4326:1	O
852	ERWINAZE.xml:S1:4328:3	O
,	ERWINAZE.xml:S1:4331:1	O
intravenous	ERWINAZE.xml:S1:4333:11	O
n	ERWINAZE.xml:S1:4345:1	O
29	ERWINAZE.xml:S1:4347:2	O
,	ERWINAZE.xml:S1:4349:1	O
other	ERWINAZE.xml:S1:4351:5	O
or	ERWINAZE.xml:S1:4357:2	O
unknown	ERWINAZE.xml:S1:4360:7	O
n	ERWINAZE.xml:S1:4368:1	O
59	ERWINAZE.xml:S1:4370:2	O
.	ERWINAZE.xml:S1:4372:1	O

In	ERWINAZE.xml:S1:4374:2	O
the	ERWINAZE.xml:S1:4377:3	O
EMTP	ERWINAZE.xml:S1:4381:4	O
trial	ERWINAZE.xml:S1:4386:5	O
,	ERWINAZE.xml:S1:4391:1	O
the	ERWINAZE.xml:S1:4393:3	O
planned	ERWINAZE.xml:S1:4397:7	O
number	ERWINAZE.xml:S1:4405:6	O
of	ERWINAZE.xml:S1:4412:2	O
doses	ERWINAZE.xml:S1:4415:5	O
of	ERWINAZE.xml:S1:4421:2	O
ERWINAZE	ERWINAZE.xml:S1:4424:8	O
ranged	ERWINAZE.xml:S1:4433:6	O
from	ERWINAZE.xml:S1:4440:4	O
3	ERWINAZE.xml:S1:4445:1	O
to	ERWINAZE.xml:S1:4447:2	O
48	ERWINAZE.xml:S1:4450:2	O
doses	ERWINAZE.xml:S1:4453:5	O
.	ERWINAZE.xml:S1:4458:1	O

Seventy	ERWINAZE.xml:S1:4460:7	O
-	ERWINAZE.xml:S1:4467:1	O
eight	ERWINAZE.xml:S1:4468:5	O
percent	ERWINAZE.xml:S1:4474:7	O
of	ERWINAZE.xml:S1:4482:2	O
patients	ERWINAZE.xml:S1:4485:8	O
(	ERWINAZE.xml:S1:4494:1	O
693	ERWINAZE.xml:S1:4495:3	O
of	ERWINAZE.xml:S1:4499:2	O
893	ERWINAZE.xml:S1:4502:3	O
)	ERWINAZE.xml:S1:4505:1	O
were	ERWINAZE.xml:S1:4507:4	O
able	ERWINAZE.xml:S1:4512:4	O
to	ERWINAZE.xml:S1:4517:2	O
receive	ERWINAZE.xml:S1:4520:7	O
all	ERWINAZE.xml:S1:4528:3	O
planned	ERWINAZE.xml:S1:4532:7	O
doses	ERWINAZE.xml:S1:4540:5	O
to	ERWINAZE.xml:S1:4546:2	O
complete	ERWINAZE.xml:S1:4549:8	O
their	ERWINAZE.xml:S1:4558:5	O
prescribed	ERWINAZE.xml:S1:4564:10	O
treatment	ERWINAZE.xml:S1:4575:9	O
regimen	ERWINAZE.xml:S1:4585:7	O
.	ERWINAZE.xml:S1:4592:1	O

In	ERWINAZE.xml:S1:4598:2	O
Study	ERWINAZE.xml:S1:4601:5	O
1	ERWINAZE.xml:S1:4607:1	O
and	ERWINAZE.xml:S1:4609:3	O
Study	ERWINAZE.xml:S1:4613:5	O
2	ERWINAZE.xml:S1:4619:1	O
,	ERWINAZE.xml:S1:4620:1	O
safety	ERWINAZE.xml:S1:4622:6	O
information	ERWINAZE.xml:S1:4629:11	O
was	ERWINAZE.xml:S1:4641:3	O
prospectively	ERWINAZE.xml:S1:4645:13	O
and	ERWINAZE.xml:S1:4659:3	O
systematically	ERWINAZE.xml:S1:4663:14	O
collected	ERWINAZE.xml:S1:4678:9	O
.	ERWINAZE.xml:S1:4687:1	O

In	ERWINAZE.xml:S1:4689:2	O
Study	ERWINAZE.xml:S1:4692:5	O
1	ERWINAZE.xml:S1:4698:1	O
,	ERWINAZE.xml:S1:4699:1	O
all	ERWINAZE.xml:S1:4701:3	O
Grades	ERWINAZE.xml:S1:4705:6	O
of	ERWINAZE.xml:S1:4712:2	O
adverse	ERWINAZE.xml:S1:4715:7	O
events	ERWINAZE.xml:S1:4723:6	O
were	ERWINAZE.xml:S1:4730:4	O
reported	ERWINAZE.xml:S1:4735:8	O
for	ERWINAZE.xml:S1:4744:3	O
the	ERWINAZE.xml:S1:4748:3	O
following	ERWINAZE.xml:S1:4752:9	O
adverse	ERWINAZE.xml:S1:4762:7	O
events	ERWINAZE.xml:S1:4770:6	O
of	ERWINAZE.xml:S1:4777:2	O
special	ERWINAZE.xml:S1:4780:7	O
interest	ERWINAZE.xml:S1:4788:8	O
:	ERWINAZE.xml:S1:4796:1	O
allergy	ERWINAZE.xml:S1:4798:7	B-AdverseReaction
,	ERWINAZE.xml:S1:4805:1	O
pancreatitis	ERWINAZE.xml:S1:4807:12	B-AdverseReaction
,	ERWINAZE.xml:S1:4819:1	O
coagulopathy	ERWINAZE.xml:S1:4821:12	B-AdverseReaction
(	ERWINAZE.xml:S1:4834:1	O
hemorrhage	ERWINAZE.xml:S1:4835:10	B-AdverseReaction
,	ERWINAZE.xml:S1:4845:1	O
thrombosis	ERWINAZE.xml:S1:4847:10	B-AdverseReaction
or	ERWINAZE.xml:S1:4858:2	O
infarct	ERWINAZE.xml:S1:4861:7	B-AdverseReaction
)	ERWINAZE.xml:S1:4868:1	O
,	ERWINAZE.xml:S1:4869:1	O
hyperbilirubinemia	ERWINAZE.xml:S1:4871:18	B-AdverseReaction
,	ERWINAZE.xml:S1:4889:1	O
hyperglycemia	ERWINAZE.xml:S1:4891:13	B-AdverseReaction
,	ERWINAZE.xml:S1:4904:1	O
hyperlipidemia	ERWINAZE.xml:S1:4906:14	B-AdverseReaction
,	ERWINAZE.xml:S1:4920:1	O
ketoacidosis	ERWINAZE.xml:S1:4922:12	B-AdverseReaction
,	ERWINAZE.xml:S1:4934:1	O
and	ERWINAZE.xml:S1:4936:3	O
CNS	ERWINAZE.xml:S1:4940:3	B-AdverseReaction
events	ERWINAZE.xml:S1:4944:6	I-AdverseReaction
(	ERWINAZE.xml:S1:4951:1	O
hemorrhage	ERWINAZE.xml:S1:4952:10	I-AdverseReaction
,	ERWINAZE.xml:S1:4962:1	O
thrombosis	ERWINAZE.xml:S1:4964:10	I-AdverseReaction
or	ERWINAZE.xml:S1:4975:2	O
infarction	ERWINAZE.xml:S1:4978:10	I-AdverseReaction
,	ERWINAZE.xml:S1:4988:1	O
and	ERWINAZE.xml:S1:4990:3	O
cerebral	ERWINAZE.xml:S1:4994:8	B-AdverseReaction
venous	ERWINAZE.xml:S1:5003:6	I-AdverseReaction
thrombosis	ERWINAZE.xml:S1:5010:10	I-AdverseReaction
)	ERWINAZE.xml:S1:5020:1	O
and	ERWINAZE.xml:S1:5022:3	O
only	ERWINAZE.xml:S1:5026:4	O
Grade	ERWINAZE.xml:S1:5031:5	O
3	ERWINAZE.xml:S1:5037:1	O
and	ERWINAZE.xml:S1:5039:3	O
4	ERWINAZE.xml:S1:5043:1	O
events	ERWINAZE.xml:S1:5045:6	O
were	ERWINAZE.xml:S1:5052:4	O
reported	ERWINAZE.xml:S1:5057:8	O
for	ERWINAZE.xml:S1:5066:3	O
other	ERWINAZE.xml:S1:5070:5	O
adverse	ERWINAZE.xml:S1:5076:7	O
events	ERWINAZE.xml:S1:5084:6	O
.	ERWINAZE.xml:S1:5090:1	O

In	ERWINAZE.xml:S1:5092:2	O
Study	ERWINAZE.xml:S1:5095:5	O
2	ERWINAZE.xml:S1:5101:1	O
all	ERWINAZE.xml:S1:5103:3	O
adverse	ERWINAZE.xml:S1:5107:7	O
events	ERWINAZE.xml:S1:5115:6	O
of	ERWINAZE.xml:S1:5122:2	O
all	ERWINAZE.xml:S1:5125:3	O
Grades	ERWINAZE.xml:S1:5129:6	O
were	ERWINAZE.xml:S1:5136:4	O
prospectively	ERWINAZE.xml:S1:5141:13	O
collected	ERWINAZE.xml:S1:5155:9	O
.	ERWINAZE.xml:S1:5164:1	O

In	ERWINAZE.xml:S1:5166:2	O
the	ERWINAZE.xml:S1:5169:3	O
EMTP	ERWINAZE.xml:S1:5173:4	O
trial	ERWINAZE.xml:S1:5178:5	O
,	ERWINAZE.xml:S1:5183:1	O
safety	ERWINAZE.xml:S1:5185:6	O
data	ERWINAZE.xml:S1:5192:4	O
were	ERWINAZE.xml:S1:5197:4	O
derived	ERWINAZE.xml:S1:5202:7	O
from	ERWINAZE.xml:S1:5210:4	O
case	ERWINAZE.xml:S1:5215:4	O
report	ERWINAZE.xml:S1:5220:6	O
forms	ERWINAZE.xml:S1:5227:5	O
that	ERWINAZE.xml:S1:5233:4	O
collected	ERWINAZE.xml:S1:5238:9	O
adverse	ERWINAZE.xml:S1:5248:7	O
event	ERWINAZE.xml:S1:5256:5	O
information	ERWINAZE.xml:S1:5262:11	O
.	ERWINAZE.xml:S1:5273:1	O

The	ERWINAZE.xml:S1:5275:3	O
forms	ERWINAZE.xml:S1:5279:5	B-Factor
specifically	ERWINAZE.xml:S1:5285:12	I-Factor
requested	ERWINAZE.xml:S1:5298:9	I-Factor
information	ERWINAZE.xml:S1:5308:11	I-Factor
on	ERWINAZE.xml:S1:5320:2	O
occurrence	ERWINAZE.xml:S1:5323:10	O
of	ERWINAZE.xml:S1:5334:2	O
allergic	ERWINAZE.xml:S1:5337:8	B-AdverseReaction
reactions	ERWINAZE.xml:S1:5346:9	I-AdverseReaction
,	ERWINAZE.xml:S1:5355:1	O
thrombotic	ERWINAZE.xml:S1:5357:10	B-AdverseReaction
events	ERWINAZE.xml:S1:5368:6	I-AdverseReaction
,	ERWINAZE.xml:S1:5374:1	O
hemorrhagic	ERWINAZE.xml:S1:5376:11	B-AdverseReaction
events	ERWINAZE.xml:S1:5388:6	I-AdverseReaction
,	ERWINAZE.xml:S1:5394:1	O
hepatobiliary	ERWINAZE.xml:S1:5396:13	B-AdverseReaction
disorders	ERWINAZE.xml:S1:5410:9	I-AdverseReaction
,	ERWINAZE.xml:S1:5419:1	O
pancreatic	ERWINAZE.xml:S1:5421:10	B-AdverseReaction
disorders	ERWINAZE.xml:S1:5432:9	I-AdverseReaction
,	ERWINAZE.xml:S1:5441:1	O
and	ERWINAZE.xml:S1:5443:3	O
hyperglycemia	ERWINAZE.xml:S1:5447:13	B-AdverseReaction
.	ERWINAZE.xml:S1:5460:1	O

The	ERWINAZE.xml:S1:5466:3	O
incidence	ERWINAZE.xml:S1:5470:9	O
of	ERWINAZE.xml:S1:5480:2	O
non	ERWINAZE.xml:S1:5483:3	O
-	ERWINAZE.xml:S1:5486:1	O
hematologic	ERWINAZE.xml:S1:5487:11	O
,	ERWINAZE.xml:S1:5498:1	O
non	ERWINAZE.xml:S1:5500:3	O
-	ERWINAZE.xml:S1:5503:1	O
infectious	ERWINAZE.xml:S1:5504:10	O
,	ERWINAZE.xml:S1:5514:1	O
adverse	ERWINAZE.xml:S1:5516:7	O
events	ERWINAZE.xml:S1:5524:6	O
(	ERWINAZE.xml:S1:5531:1	O
all	ERWINAZE.xml:S1:5532:3	O
Grades	ERWINAZE.xml:S1:5536:6	O
)	ERWINAZE.xml:S1:5542:1	O
in	ERWINAZE.xml:S1:5544:2	O
Study	ERWINAZE.xml:S1:5547:5	O
1	ERWINAZE.xml:S1:5553:1	O
,	ERWINAZE.xml:S1:5554:1	O
Study	ERWINAZE.xml:S1:5556:5	O
2	ERWINAZE.xml:S1:5562:1	O
,	ERWINAZE.xml:S1:5563:1	O
and	ERWINAZE.xml:S1:5565:3	O
the	ERWINAZE.xml:S1:5569:3	O
EMTP	ERWINAZE.xml:S1:5573:4	O
trial	ERWINAZE.xml:S1:5578:5	O
is	ERWINAZE.xml:S1:5584:2	O
provided	ERWINAZE.xml:S1:5587:8	O
in	ERWINAZE.xml:S1:5596:2	O
Table	ERWINAZE.xml:S1:5599:5	O
1	ERWINAZE.xml:S1:5605:1	O
.	ERWINAZE.xml:S1:5606:1	O

The	ERWINAZE.xml:S1:5612:3	O
incidence	ERWINAZE.xml:S1:5616:9	O
of	ERWINAZE.xml:S1:5626:2	O
Grade	ERWINAZE.xml:S1:5629:5	O
3	ERWINAZE.xml:S1:5635:1	O
or	ERWINAZE.xml:S1:5637:2	O
greater	ERWINAZE.xml:S1:5640:7	O
non	ERWINAZE.xml:S1:5648:3	O
-	ERWINAZE.xml:S1:5651:1	O
hematologic	ERWINAZE.xml:S1:5652:11	O
,	ERWINAZE.xml:S1:5663:1	O
non	ERWINAZE.xml:S1:5665:3	O
-	ERWINAZE.xml:S1:5668:1	O
infectious	ERWINAZE.xml:S1:5669:10	O
adverse	ERWINAZE.xml:S1:5680:7	O
reactions	ERWINAZE.xml:S1:5688:9	O
occurring	ERWINAZE.xml:S1:5698:9	O
with	ERWINAZE.xml:S1:5708:4	O
ERWINAZE	ERWINAZE.xml:S1:5713:8	O
in	ERWINAZE.xml:S1:5722:2	O
Study	ERWINAZE.xml:S1:5725:5	O
1	ERWINAZE.xml:S1:5731:1	O
,	ERWINAZE.xml:S1:5732:1	O
Study	ERWINAZE.xml:S1:5734:5	O
2	ERWINAZE.xml:S1:5740:1	O
and	ERWINAZE.xml:S1:5742:3	O
EMTP	ERWINAZE.xml:S1:5746:4	O
trial	ERWINAZE.xml:S1:5751:5	O
is	ERWINAZE.xml:S1:5757:2	O
provided	ERWINAZE.xml:S1:5760:8	O
in	ERWINAZE.xml:S1:5769:2	O
Table	ERWINAZE.xml:S1:5772:5	O
2	ERWINAZE.xml:S1:5778:1	O
.	ERWINAZE.xml:S1:5779:1	O

Table	ERWINAZE.xml:S1:5786:5	O
1	ERWINAZE.xml:S1:5792:1	O
Table	ERWINAZE.xml:S1:5795:5	O
2	ERWINAZE.xml:S1:5801:1	O
6.2	ERWINAZE.xml:S1:5805:3	O
Immunogenicity	ERWINAZE.xml:S1:5809:14	O

As	ERWINAZE.xml:S1:5827:2	O
with	ERWINAZE.xml:S1:5830:4	O
most	ERWINAZE.xml:S1:5835:4	O
therapeutic	ERWINAZE.xml:S1:5840:11	O
proteins	ERWINAZE.xml:S1:5852:8	O
,	ERWINAZE.xml:S1:5860:1	O
patients	ERWINAZE.xml:S1:5862:8	O
may	ERWINAZE.xml:S1:5871:3	O
develop	ERWINAZE.xml:S1:5875:7	O
anti	ERWINAZE.xml:S1:5883:4	O
-	ERWINAZE.xml:S1:5887:1	O
drug	ERWINAZE.xml:S1:5888:4	O
antibodies	ERWINAZE.xml:S1:5893:10	O
(	ERWINAZE.xml:S1:5904:1	O
ADA	ERWINAZE.xml:S1:5905:3	O
)	ERWINAZE.xml:S1:5908:1	O
to	ERWINAZE.xml:S1:5910:2	O
ERWINAZE	ERWINAZE.xml:S1:5913:8	O
.	ERWINAZE.xml:S1:5921:1	O
In	ERWINAZE.xml:S1:5922:2	O
a	ERWINAZE.xml:S1:5925:1	O
study	ERWINAZE.xml:S1:5927:5	O
with	ERWINAZE.xml:S1:5933:4	O
ERWINAZE	ERWINAZE.xml:S1:5938:8	O
treatment	ERWINAZE.xml:S1:5947:9	O
by	ERWINAZE.xml:S1:5957:2	O
intramuscular	ERWINAZE.xml:S1:5960:13	O
administration	ERWINAZE.xml:S1:5974:14	O
(	ERWINAZE.xml:S1:5989:1	O
Study	ERWINAZE.xml:S1:5990:5	O
1	ERWINAZE.xml:S1:5996:1	O
)	ERWINAZE.xml:S1:5997:1	O
,	ERWINAZE.xml:S1:5998:1	O
6	ERWINAZE.xml:S1:6000:1	O
of	ERWINAZE.xml:S1:6002:2	O
56	ERWINAZE.xml:S1:6005:2	O
(	ERWINAZE.xml:S1:6008:1	O
11%	ERWINAZE.xml:S1:6009:3	O
)	ERWINAZE.xml:S1:6012:1	O
patients	ERWINAZE.xml:S1:6014:8	O
treated	ERWINAZE.xml:S1:6023:7	O
with	ERWINAZE.xml:S1:6031:4	O
ERWINAZE	ERWINAZE.xml:S1:6036:8	O
developed	ERWINAZE.xml:S1:6045:9	O
antibodies	ERWINAZE.xml:S1:6055:10	O
to	ERWINAZE.xml:S1:6066:2	O
ERWINAZE	ERWINAZE.xml:S1:6069:8	O
.	ERWINAZE.xml:S1:6077:1	O

Of	ERWINAZE.xml:S1:6079:2	O
these	ERWINAZE.xml:S1:6082:5	O
6	ERWINAZE.xml:S1:6088:1	O
ADA	ERWINAZE.xml:S1:6090:3	O
positive	ERWINAZE.xml:S1:6094:8	O
patients	ERWINAZE.xml:S1:6103:8	O
,	ERWINAZE.xml:S1:6111:1	O
one	ERWINAZE.xml:S1:6113:3	O
experienced	ERWINAZE.xml:S1:6117:11	O
a	ERWINAZE.xml:S1:6129:1	O
hypersensitivity	ERWINAZE.xml:S1:6131:16	B-AdverseReaction
reaction	ERWINAZE.xml:S1:6148:8	I-AdverseReaction
during	ERWINAZE.xml:S1:6157:6	O
Study	ERWINAZE.xml:S1:6164:5	O
1	ERWINAZE.xml:S1:6170:1	O
(	ERWINAZE.xml:S1:6172:1	O
2%	ERWINAZE.xml:S1:6173:2	O
,	ERWINAZE.xml:S1:6175:1	O
1	ERWINAZE.xml:S1:6177:1	O
of	ERWINAZE.xml:S1:6179:2	O
56	ERWINAZE.xml:S1:6182:2	O
)	ERWINAZE.xml:S1:6184:1	O
.	ERWINAZE.xml:S1:6185:1	O

None	ERWINAZE.xml:S1:6187:4	O
of	ERWINAZE.xml:S1:6192:2	O
these	ERWINAZE.xml:S1:6195:5	O
6	ERWINAZE.xml:S1:6201:1	O
patients	ERWINAZE.xml:S1:6203:8	O
had	ERWINAZE.xml:S1:6212:3	O
neutralizing	ERWINAZE.xml:S1:6216:12	O
antibodies	ERWINAZE.xml:S1:6229:10	O
.	ERWINAZE.xml:S1:6239:1	O
In	ERWINAZE.xml:S1:6240:2	O
a	ERWINAZE.xml:S1:6243:1	O
study	ERWINAZE.xml:S1:6245:5	O
with	ERWINAZE.xml:S1:6251:4	O
ERWINAZE	ERWINAZE.xml:S1:6256:8	O
treatment	ERWINAZE.xml:S1:6265:9	O
by	ERWINAZE.xml:S1:6275:2	O
intravenous	ERWINAZE.xml:S1:6278:11	O
administration	ERWINAZE.xml:S1:6290:14	O
(	ERWINAZE.xml:S1:6305:1	O
Study	ERWINAZE.xml:S1:6306:5	O
2	ERWINAZE.xml:S1:6312:1	O
)	ERWINAZE.xml:S1:6313:1	O
,	ERWINAZE.xml:S1:6314:1	O
4	ERWINAZE.xml:S1:6316:1	O
of	ERWINAZE.xml:S1:6318:2	O
30	ERWINAZE.xml:S1:6321:2	O
(	ERWINAZE.xml:S1:6324:1	O
13.3%	ERWINAZE.xml:S1:6325:5	O
)	ERWINAZE.xml:S1:6330:1	O
patients	ERWINAZE.xml:S1:6332:8	O
treated	ERWINAZE.xml:S1:6341:7	O
with	ERWINAZE.xml:S1:6349:4	O
ERWINAZE	ERWINAZE.xml:S1:6354:8	O
developed	ERWINAZE.xml:S1:6363:9	O
anti	ERWINAZE.xml:S1:6373:4	O
-	ERWINAZE.xml:S1:6377:1	O
ERWINAZE	ERWINAZE.xml:S1:6378:8	O
antibodies	ERWINAZE.xml:S1:6387:10	O
.	ERWINAZE.xml:S1:6397:1	O

Of	ERWINAZE.xml:S1:6399:2	O
these	ERWINAZE.xml:S1:6402:5	O
4	ERWINAZE.xml:S1:6408:1	O
patients	ERWINAZE.xml:S1:6410:8	O
who	ERWINAZE.xml:S1:6419:3	O
developed	ERWINAZE.xml:S1:6423:9	O
anti	ERWINAZE.xml:S1:6433:4	O
-	ERWINAZE.xml:S1:6437:1	O
ERWINAZE	ERWINAZE.xml:S1:6438:8	O
antibodies	ERWINAZE.xml:S1:6447:10	O
,	ERWINAZE.xml:S1:6457:1	O
3	ERWINAZE.xml:S1:6459:1	O
experienced	ERWINAZE.xml:S1:6461:11	O
hypersensitivity	ERWINAZE.xml:S1:6473:16	B-AdverseReaction
reactions	ERWINAZE.xml:S1:6490:9	I-AdverseReaction
(	ERWINAZE.xml:S1:6500:1	O
10%	ERWINAZE.xml:S1:6501:3	O
,	ERWINAZE.xml:S1:6504:1	O
3	ERWINAZE.xml:S1:6506:1	O
of	ERWINAZE.xml:S1:6508:2	O
30	ERWINAZE.xml:S1:6511:2	O
)	ERWINAZE.xml:S1:6513:1	O
during	ERWINAZE.xml:S1:6515:6	O
the	ERWINAZE.xml:S1:6522:3	O
study	ERWINAZE.xml:S1:6526:5	O
.	ERWINAZE.xml:S1:6531:1	O

None	ERWINAZE.xml:S1:6533:4	O
of	ERWINAZE.xml:S1:6538:2	O
these	ERWINAZE.xml:S1:6541:5	O
4	ERWINAZE.xml:S1:6547:1	O
patients	ERWINAZE.xml:S1:6549:8	O
had	ERWINAZE.xml:S1:6558:3	O
neutralizing	ERWINAZE.xml:S1:6562:12	O
antibodies	ERWINAZE.xml:S1:6575:10	O
.	ERWINAZE.xml:S1:6585:1	O
The	ERWINAZE.xml:S1:6586:3	O
presence	ERWINAZE.xml:S1:6590:8	O
of	ERWINAZE.xml:S1:6599:2	O
ADA	ERWINAZE.xml:S1:6602:3	O
to	ERWINAZE.xml:S1:6606:2	O
ERWINAZE	ERWINAZE.xml:S1:6609:8	O
is	ERWINAZE.xml:S1:6618:2	O
associated	ERWINAZE.xml:S1:6621:10	O
with	ERWINAZE.xml:S1:6632:4	O
a	ERWINAZE.xml:S1:6637:1	O
higher	ERWINAZE.xml:S1:6639:6	O
risk	ERWINAZE.xml:S1:6646:4	B-Factor
of	ERWINAZE.xml:S1:6651:2	O
hypersensitivity	ERWINAZE.xml:S1:6654:16	B-AdverseReaction
reactions	ERWINAZE.xml:S1:6671:9	I-AdverseReaction
in	ERWINAZE.xml:S1:6681:2	O
patients	ERWINAZE.xml:S1:6684:8	O
who	ERWINAZE.xml:S1:6693:3	O
received	ERWINAZE.xml:S1:6697:8	O
ERWINAZE	ERWINAZE.xml:S1:6706:8	O
through	ERWINAZE.xml:S1:6715:7	O
intravenous	ERWINAZE.xml:S1:6723:11	O
infusion	ERWINAZE.xml:S1:6735:8	O
compared	ERWINAZE.xml:S1:6744:8	O
to	ERWINAZE.xml:S1:6753:2	O
intramuscular	ERWINAZE.xml:S1:6756:13	O
administration	ERWINAZE.xml:S1:6770:14	O
of	ERWINAZE.xml:S1:6785:2	O
ERWINAZE	ERWINAZE.xml:S1:6788:8	O
.	ERWINAZE.xml:S1:6796:1	O
Immunogenicity	ERWINAZE.xml:S1:6797:14	O
assay	ERWINAZE.xml:S1:6812:5	O
are	ERWINAZE.xml:S1:6818:3	O
highly	ERWINAZE.xml:S1:6822:6	O
dependent	ERWINAZE.xml:S1:6829:9	O
on	ERWINAZE.xml:S1:6839:2	O
the	ERWINAZE.xml:S1:6842:3	O
sensitivity	ERWINAZE.xml:S1:6846:11	O
and	ERWINAZE.xml:S1:6858:3	O
specificity	ERWINAZE.xml:S1:6862:11	O
of	ERWINAZE.xml:S1:6874:2	O
the	ERWINAZE.xml:S1:6877:3	O
assay	ERWINAZE.xml:S1:6881:5	O
and	ERWINAZE.xml:S1:6887:3	O
may	ERWINAZE.xml:S1:6891:3	O
be	ERWINAZE.xml:S1:6895:2	O
influenced	ERWINAZE.xml:S1:6898:10	O
by	ERWINAZE.xml:S1:6909:2	O
several	ERWINAZE.xml:S1:6912:7	O
factors	ERWINAZE.xml:S1:6920:7	O
such	ERWINAZE.xml:S1:6928:4	O
as	ERWINAZE.xml:S1:6933:2	O
:	ERWINAZE.xml:S1:6935:1	O
assay	ERWINAZE.xml:S1:6937:5	O
methodology	ERWINAZE.xml:S1:6943:11	O
,	ERWINAZE.xml:S1:6954:1	O
sample	ERWINAZE.xml:S1:6956:6	O
handling	ERWINAZE.xml:S1:6963:8	O
,	ERWINAZE.xml:S1:6971:1	O
timing	ERWINAZE.xml:S1:6973:6	O
of	ERWINAZE.xml:S1:6980:2	O
sample	ERWINAZE.xml:S1:6983:6	O
collection	ERWINAZE.xml:S1:6990:10	O
,	ERWINAZE.xml:S1:7000:1	O
concomitant	ERWINAZE.xml:S1:7002:11	O
medications	ERWINAZE.xml:S1:7014:11	O
,	ERWINAZE.xml:S1:7025:1	O
and	ERWINAZE.xml:S1:7027:3	O
underlying	ERWINAZE.xml:S1:7031:10	O
disease	ERWINAZE.xml:S1:7042:7	O
.	ERWINAZE.xml:S1:7049:1	O

For	ERWINAZE.xml:S1:7051:3	O
these	ERWINAZE.xml:S1:7055:5	O
reasons	ERWINAZE.xml:S1:7061:7	O
,	ERWINAZE.xml:S1:7068:1	O
comparison	ERWINAZE.xml:S1:7070:10	O
of	ERWINAZE.xml:S1:7081:2	O
the	ERWINAZE.xml:S1:7084:3	O
incidence	ERWINAZE.xml:S1:7088:9	O
of	ERWINAZE.xml:S1:7098:2	O
antibodies	ERWINAZE.xml:S1:7101:10	O
to	ERWINAZE.xml:S1:7112:2	O
ERWINAZE	ERWINAZE.xml:S1:7115:8	O
with	ERWINAZE.xml:S1:7124:4	O
the	ERWINAZE.xml:S1:7129:3	O
incidence	ERWINAZE.xml:S1:7133:9	O
of	ERWINAZE.xml:S1:7143:2	O
antibodies	ERWINAZE.xml:S1:7146:10	O
to	ERWINAZE.xml:S1:7157:2	O
other	ERWINAZE.xml:S1:7160:5	O
products	ERWINAZE.xml:S1:7166:8	O
may	ERWINAZE.xml:S1:7175:3	O
be	ERWINAZE.xml:S1:7179:2	O
misleading	ERWINAZE.xml:S1:7182:10	O
.	ERWINAZE.xml:S1:7192:1	O
5	ERWINAZE.xml:S2:4:1	O
WARNINGS	ERWINAZE.xml:S2:6:8	O
AND	ERWINAZE.xml:S2:15:3	O
PRECAUTIONS	ERWINAZE.xml:S2:19:11	O

EXCERPT	ERWINAZE.xml:S2:35:7	O
:	ERWINAZE.xml:S2:42:1	O
If	ERWINAZE.xml:S2:52:2	O
the	ERWINAZE.xml:S2:55:3	O
following	ERWINAZE.xml:S2:59:9	O
occur	ERWINAZE.xml:S2:69:5	O
,	ERWINAZE.xml:S2:74:1	O
discontinue	ERWINAZE.xml:S2:76:11	O
ERWINAZE	ERWINAZE.xml:S2:88:8	O
:	ERWINAZE.xml:S2:96:1	O
Serious	ERWINAZE.xml:S2:97:7	B-Severity
hypersensitivity	ERWINAZE.xml:S2:105:16	B-AdverseReaction
reactions	ERWINAZE.xml:S2:122:9	I-AdverseReaction
,	ERWINAZE.xml:S2:131:1	O
including	ERWINAZE.xml:S2:133:9	O
anaphylaxis	ERWINAZE.xml:S2:143:11	B-AdverseReaction
(	ERWINAZE.xml:S2:155:1	O
5.1	ERWINAZE.xml:S2:156:3	O
)	ERWINAZE.xml:S2:159:1	O
Severe	ERWINAZE.xml:S2:160:6	B-Severity
or	ERWINAZE.xml:S2:167:2	O
hemorrhagic	ERWINAZE.xml:S2:170:11	B-AdverseReaction
pancreatitis	ERWINAZE.xml:S2:182:12	I-AdverseReaction
(	ERWINAZE.xml:S2:195:1	O
5.2	ERWINAZE.xml:S2:196:3	O
)	ERWINAZE.xml:S2:199:1	O

Glucose	ERWINAZE.xml:S2:208:7	B-AdverseReaction
intolerance	ERWINAZE.xml:S2:216:11	I-AdverseReaction
can	ERWINAZE.xml:S2:228:3	B-Factor
occur	ERWINAZE.xml:S2:232:5	O
and	ERWINAZE.xml:S2:238:3	O
,	ERWINAZE.xml:S2:241:1	O
in	ERWINAZE.xml:S2:243:2	O
some	ERWINAZE.xml:S2:246:4	O
cases	ERWINAZE.xml:S2:251:5	O
,	ERWINAZE.xml:S2:256:1	O
may	ERWINAZE.xml:S2:258:3	O
be	ERWINAZE.xml:S2:262:2	O
irreversible	ERWINAZE.xml:S2:265:12	B-Severity
.	ERWINAZE.xml:S2:277:1	O

Perform	ERWINAZE.xml:S2:279:7	O
appropriate	ERWINAZE.xml:S2:287:11	O
monitoring	ERWINAZE.xml:S2:299:10	O
and	ERWINAZE.xml:S2:310:3	O
treat	ERWINAZE.xml:S2:314:5	O
hyperglycemia	ERWINAZE.xml:S2:320:13	O
with	ERWINAZE.xml:S2:334:4	O
insulin	ERWINAZE.xml:S2:339:7	O
,	ERWINAZE.xml:S2:346:1	O
as	ERWINAZE.xml:S2:348:2	O
necessary	ERWINAZE.xml:S2:351:9	O
(	ERWINAZE.xml:S2:361:1	O
5.3	ERWINAZE.xml:S2:362:3	O
)	ERWINAZE.xml:S2:365:1	O

Thrombosis	ERWINAZE.xml:S2:374:10	B-AdverseReaction
,	ERWINAZE.xml:S2:384:1	O
hemorrhage	ERWINAZE.xml:S2:386:10	B-AdverseReaction
:	ERWINAZE.xml:S2:396:1	O
discontinue	ERWINAZE.xml:S2:398:11	O
ERWINAZE	ERWINAZE.xml:S2:410:8	O
until	ERWINAZE.xml:S2:419:5	O
resolved	ERWINAZE.xml:S2:425:8	O
(	ERWINAZE.xml:S2:434:1	O
5.4	ERWINAZE.xml:S2:435:3	O
)	ERWINAZE.xml:S2:438:1	O

5.1	ERWINAZE.xml:S2:449:3	O

Hypersensitivity	ERWINAZE.xml:S2:453:16	O
Reactions	ERWINAZE.xml:S2:470:9	O

Grade	ERWINAZE.xml:S2:485:5	B-Severity
3	ERWINAZE.xml:S2:491:1	I-Severity
and	ERWINAZE.xml:S2:493:3	O
4	ERWINAZE.xml:S2:497:1	I-Severity
hypersensitivity	ERWINAZE.xml:S2:499:16	B-AdverseReaction
reactions	ERWINAZE.xml:S2:516:9	I-AdverseReaction
after	ERWINAZE.xml:S2:526:5	O
the	ERWINAZE.xml:S2:532:3	O
use	ERWINAZE.xml:S2:536:3	O
of	ERWINAZE.xml:S2:540:2	O
ERWINAZE	ERWINAZE.xml:S2:543:8	O
have	ERWINAZE.xml:S2:552:4	O
occurred	ERWINAZE.xml:S2:557:8	O
in	ERWINAZE.xml:S2:566:2	O
5%	ERWINAZE.xml:S2:569:2	O
of	ERWINAZE.xml:S2:572:2	O
patients	ERWINAZE.xml:S2:575:8	O
in	ERWINAZE.xml:S2:584:2	O
clinical	ERWINAZE.xml:S2:587:8	O
trials	ERWINAZE.xml:S2:596:6	O
[	ERWINAZE.xml:S2:603:1	O
see	ERWINAZE.xml:S2:606:3	O
Adverse	ERWINAZE.xml:S2:610:7	O
Reactions	ERWINAZE.xml:S2:618:9	O
(	ERWINAZE.xml:S2:628:1	O
6.1	ERWINAZE.xml:S2:629:3	O
)	ERWINAZE.xml:S2:632:1	O
]	ERWINAZE.xml:S2:635:1	O
.	ERWINAZE.xml:S2:636:1	O

Administer	ERWINAZE.xml:S2:644:10	O
this	ERWINAZE.xml:S2:655:4	O
product	ERWINAZE.xml:S2:660:7	O
in	ERWINAZE.xml:S2:668:2	O
a	ERWINAZE.xml:S2:671:1	O
setting	ERWINAZE.xml:S2:673:7	O
with	ERWINAZE.xml:S2:681:4	O
resuscitation	ERWINAZE.xml:S2:686:13	O
equipment	ERWINAZE.xml:S2:700:9	O
and	ERWINAZE.xml:S2:710:3	O
other	ERWINAZE.xml:S2:714:5	O
agents	ERWINAZE.xml:S2:720:6	O
necessary	ERWINAZE.xml:S2:727:9	O
to	ERWINAZE.xml:S2:737:2	O
treat	ERWINAZE.xml:S2:740:5	O
anaphylaxis	ERWINAZE.xml:S2:746:11	O
.	ERWINAZE.xml:S2:757:1	O

If	ERWINAZE.xml:S2:759:2	O
a	ERWINAZE.xml:S2:762:1	O
serious	ERWINAZE.xml:S2:764:7	O
hypersensitivity	ERWINAZE.xml:S2:772:16	O
reaction	ERWINAZE.xml:S2:789:8	O
occurs	ERWINAZE.xml:S2:798:6	O
,	ERWINAZE.xml:S2:804:1	O
discontinue	ERWINAZE.xml:S2:806:11	O
ERWINAZE	ERWINAZE.xml:S2:818:8	O
and	ERWINAZE.xml:S2:827:3	O
initiate	ERWINAZE.xml:S2:831:8	O
appropriate	ERWINAZE.xml:S2:840:11	O
therapy	ERWINAZE.xml:S2:852:7	O
.	ERWINAZE.xml:S2:859:1	O

5.2	ERWINAZE.xml:S2:867:3	O
Pancreatitis	ERWINAZE.xml:S2:871:12	O

Pancreatitis	ERWINAZE.xml:S2:889:12	B-AdverseReaction
has	ERWINAZE.xml:S2:902:3	O
been	ERWINAZE.xml:S2:906:4	O
reported	ERWINAZE.xml:S2:911:8	O
in	ERWINAZE.xml:S2:920:2	O
4%	ERWINAZE.xml:S2:923:2	O
of	ERWINAZE.xml:S2:926:2	O
patients	ERWINAZE.xml:S2:929:8	O
in	ERWINAZE.xml:S2:938:2	O
clinical	ERWINAZE.xml:S2:941:8	O
trials	ERWINAZE.xml:S2:950:6	O
[	ERWINAZE.xml:S2:957:1	O
see	ERWINAZE.xml:S2:960:3	O
Adverse	ERWINAZE.xml:S2:964:7	O
Reactions	ERWINAZE.xml:S2:972:9	O
(	ERWINAZE.xml:S2:982:1	O
6.1	ERWINAZE.xml:S2:983:3	O
)	ERWINAZE.xml:S2:986:1	O
]	ERWINAZE.xml:S2:989:1	O
.	ERWINAZE.xml:S2:990:1	O

Evaluate	ERWINAZE.xml:S2:998:8	O
patients	ERWINAZE.xml:S2:1007:8	O
with	ERWINAZE.xml:S2:1016:4	O
symptoms	ERWINAZE.xml:S2:1021:8	O
compatible	ERWINAZE.xml:S2:1030:10	O
with	ERWINAZE.xml:S2:1041:4	O
pancreatitis	ERWINAZE.xml:S2:1046:12	O
to	ERWINAZE.xml:S2:1059:2	O
establish	ERWINAZE.xml:S2:1062:9	O
a	ERWINAZE.xml:S2:1072:1	O
diagnosis	ERWINAZE.xml:S2:1074:9	O
.	ERWINAZE.xml:S2:1083:1	O

Discontinue	ERWINAZE.xml:S2:1085:11	O
ERWINAZE	ERWINAZE.xml:S2:1097:8	O
for	ERWINAZE.xml:S2:1106:3	O
severe	ERWINAZE.xml:S2:1110:6	O
or	ERWINAZE.xml:S2:1117:2	O
hemorrhagic	ERWINAZE.xml:S2:1120:11	O
pancreatitis	ERWINAZE.xml:S2:1132:12	O
manifested	ERWINAZE.xml:S2:1145:10	O
by	ERWINAZE.xml:S2:1156:2	O
abdominal	ERWINAZE.xml:S2:1159:9	O
pain	ERWINAZE.xml:S2:1169:4	O
72	ERWINAZE.xml:S2:1176:2	O
hours	ERWINAZE.xml:S2:1179:5	O
and	ERWINAZE.xml:S2:1185:3	O
amylase	ERWINAZE.xml:S2:1189:7	O
elevation	ERWINAZE.xml:S2:1197:9	O
2.0	ERWINAZE.xml:S2:1210:3	O
x	ERWINAZE.xml:S2:1214:1	O
ULN	ERWINAZE.xml:S2:1216:3	O
.	ERWINAZE.xml:S2:1219:1	O

Severe	ERWINAZE.xml:S2:1221:6	O
pancreatitis	ERWINAZE.xml:S2:1228:12	O
is	ERWINAZE.xml:S2:1241:2	O
a	ERWINAZE.xml:S2:1244:1	O
contraindication	ERWINAZE.xml:S2:1246:16	O
to	ERWINAZE.xml:S2:1263:2	O
additional	ERWINAZE.xml:S2:1266:10	O
asparaginase	ERWINAZE.xml:S2:1277:12	O
administration	ERWINAZE.xml:S2:1290:14	O
.	ERWINAZE.xml:S2:1304:1	O

In	ERWINAZE.xml:S2:1306:2	O
the	ERWINAZE.xml:S2:1309:3	O
case	ERWINAZE.xml:S2:1313:4	O
of	ERWINAZE.xml:S2:1318:2	O
mild	ERWINAZE.xml:S2:1321:4	O
pancreatitis	ERWINAZE.xml:S2:1326:12	O
,	ERWINAZE.xml:S2:1338:1	O
hold	ERWINAZE.xml:S2:1340:4	O
ERWINAZE	ERWINAZE.xml:S2:1345:8	O
until	ERWINAZE.xml:S2:1354:5	O
the	ERWINAZE.xml:S2:1360:3	O
signs	ERWINAZE.xml:S2:1364:5	O
and	ERWINAZE.xml:S2:1370:3	O
symptoms	ERWINAZE.xml:S2:1374:8	O
subside	ERWINAZE.xml:S2:1383:7	O
and	ERWINAZE.xml:S2:1391:3	O
amylase	ERWINAZE.xml:S2:1395:7	O
levels	ERWINAZE.xml:S2:1403:6	O
return	ERWINAZE.xml:S2:1410:6	O
to	ERWINAZE.xml:S2:1417:2	O
normal	ERWINAZE.xml:S2:1420:6	O
.	ERWINAZE.xml:S2:1426:1	O

After	ERWINAZE.xml:S2:1428:5	O
resolution	ERWINAZE.xml:S2:1434:10	O
,	ERWINAZE.xml:S2:1444:1	O
treatment	ERWINAZE.xml:S2:1446:9	O
with	ERWINAZE.xml:S2:1456:4	O
ERWINAZE	ERWINAZE.xml:S2:1461:8	O
may	ERWINAZE.xml:S2:1470:3	O
be	ERWINAZE.xml:S2:1474:2	O
resumed	ERWINAZE.xml:S2:1477:7	O
.	ERWINAZE.xml:S2:1484:1	O

5.3	ERWINAZE.xml:S2:1492:3	O
Glucose	ERWINAZE.xml:S2:1496:7	O
Intolerance	ERWINAZE.xml:S2:1504:11	O

Glucose	ERWINAZE.xml:S2:1521:7	O
intolerance	ERWINAZE.xml:S2:1529:11	O
has	ERWINAZE.xml:S2:1541:3	O
been	ERWINAZE.xml:S2:1545:4	O
reported	ERWINAZE.xml:S2:1550:8	O
in	ERWINAZE.xml:S2:1559:2	O
5%	ERWINAZE.xml:S2:1562:2	O
of	ERWINAZE.xml:S2:1565:2	O
patients	ERWINAZE.xml:S2:1568:8	O
receiving	ERWINAZE.xml:S2:1577:9	O
ERWINAZE	ERWINAZE.xml:S2:1587:8	O
in	ERWINAZE.xml:S2:1596:2	O
clinical	ERWINAZE.xml:S2:1599:8	O
trials	ERWINAZE.xml:S2:1608:6	O
[	ERWINAZE.xml:S2:1615:1	O
see	ERWINAZE.xml:S2:1618:3	O
Adverse	ERWINAZE.xml:S2:1622:7	O
Reactions	ERWINAZE.xml:S2:1630:9	O
(	ERWINAZE.xml:S2:1646:1	O
6.1	ERWINAZE.xml:S2:1647:3	O
)	ERWINAZE.xml:S2:1650:1	O
]	ERWINAZE.xml:S2:1653:1	O
.	ERWINAZE.xml:S2:1654:1	O

In	ERWINAZE.xml:S2:1656:2	O
some	ERWINAZE.xml:S2:1659:4	O
cases	ERWINAZE.xml:S2:1664:5	O
glucose	ERWINAZE.xml:S2:1670:7	B-AdverseReaction
intolerance	ERWINAZE.xml:S2:1678:11	I-AdverseReaction
may	ERWINAZE.xml:S2:1690:3	O
be	ERWINAZE.xml:S2:1694:2	O
irreversible	ERWINAZE.xml:S2:1697:12	B-Severity
.	ERWINAZE.xml:S2:1709:1	O

Monitor	ERWINAZE.xml:S2:1711:7	O
glucose	ERWINAZE.xml:S2:1719:7	O
levels	ERWINAZE.xml:S2:1727:6	O
in	ERWINAZE.xml:S2:1734:2	O
patients	ERWINAZE.xml:S2:1737:8	O
at	ERWINAZE.xml:S2:1746:2	O
baseline	ERWINAZE.xml:S2:1749:8	O
and	ERWINAZE.xml:S2:1758:3	O
periodically	ERWINAZE.xml:S2:1762:12	O
during	ERWINAZE.xml:S2:1775:6	O
treatment	ERWINAZE.xml:S2:1782:9	O
.	ERWINAZE.xml:S2:1791:1	O

Administer	ERWINAZE.xml:S2:1793:10	O
insulin	ERWINAZE.xml:S2:1804:7	O
therapy	ERWINAZE.xml:S2:1812:7	O
as	ERWINAZE.xml:S2:1820:2	O
necessary	ERWINAZE.xml:S2:1823:9	O
in	ERWINAZE.xml:S2:1833:2	O
patients	ERWINAZE.xml:S2:1836:8	O
with	ERWINAZE.xml:S2:1845:4	O
hyperglycemia	ERWINAZE.xml:S2:1850:13	O
.	ERWINAZE.xml:S2:1863:1	O

5.4	ERWINAZE.xml:S2:1871:3	O
Thrombosis	ERWINAZE.xml:S2:1875:10	O
and	ERWINAZE.xml:S2:1886:3	O
Hemorrhage	ERWINAZE.xml:S2:1890:10	O

Serious	ERWINAZE.xml:S2:1904:7	B-Severity
thrombotic	ERWINAZE.xml:S2:1912:10	B-AdverseReaction
events	ERWINAZE.xml:S2:1923:6	I-AdverseReaction
,	ERWINAZE.xml:S2:1929:1	O
including	ERWINAZE.xml:S2:1931:9	O
sagittal	ERWINAZE.xml:S2:1941:8	B-AdverseReaction
sinus	ERWINAZE.xml:S2:1950:5	I-AdverseReaction
thrombosis	ERWINAZE.xml:S2:1956:10	I-AdverseReaction
and	ERWINAZE.xml:S2:1967:3	O
pulmonary	ERWINAZE.xml:S2:1971:9	B-AdverseReaction
embolism	ERWINAZE.xml:S2:1981:8	I-AdverseReaction
have	ERWINAZE.xml:S2:1990:4	O
been	ERWINAZE.xml:S2:1995:4	O
reported	ERWINAZE.xml:S2:2000:8	O
with	ERWINAZE.xml:S2:2009:4	O
both	ERWINAZE.xml:S2:2014:4	O
E.	ERWINAZE.xml:S2:2020:2	O
coli	ERWINAZE.xml:S2:2023:4	O
and	ERWINAZE.xml:S2:2029:3	O
Erwinia	ERWINAZE.xml:S2:2034:7	O
-	ERWINAZE.xml:S2:2043:1	O
derived	ERWINAZE.xml:S2:2044:7	O
L	ERWINAZE.xml:S2:2052:1	O
-	ERWINAZE.xml:S2:2053:1	O
asparaginase	ERWINAZE.xml:S2:2054:12	O
therapy	ERWINAZE.xml:S2:2067:7	O
.	ERWINAZE.xml:S2:2074:1	O

The	ERWINAZE.xml:S2:2076:3	O
following	ERWINAZE.xml:S2:2080:9	O
coagulation	ERWINAZE.xml:S2:2090:11	B-AdverseReaction
proteins	ERWINAZE.xml:S2:2102:8	I-AdverseReaction
were	ERWINAZE.xml:S2:2111:4	O
decreased	ERWINAZE.xml:S2:2116:9	I-AdverseReaction
in	ERWINAZE.xml:S2:2126:2	O
the	ERWINAZE.xml:S2:2129:3	O
majority	ERWINAZE.xml:S2:2133:8	O
of	ERWINAZE.xml:S2:2142:2	O
patients	ERWINAZE.xml:S2:2145:8	O
after	ERWINAZE.xml:S2:2154:5	O
a	ERWINAZE.xml:S2:2160:1	O
2	ERWINAZE.xml:S2:2162:1	O
-	ERWINAZE.xml:S2:2163:1	O
week	ERWINAZE.xml:S2:2164:4	O
course	ERWINAZE.xml:S2:2169:6	O
of	ERWINAZE.xml:S2:2176:2	O
ERWINAZE	ERWINAZE.xml:S2:2179:8	O
by	ERWINAZE.xml:S2:2188:2	O
intramuscular	ERWINAZE.xml:S2:2191:13	O
administration	ERWINAZE.xml:S2:2205:14	O
:	ERWINAZE.xml:S2:2219:1	O
fibrinogen	ERWINAZE.xml:S2:2221:10	I-AdverseReaction
,	ERWINAZE.xml:S2:2231:1	O
protein	ERWINAZE.xml:S2:2233:7	I-AdverseReaction
C	ERWINAZE.xml:S2:2241:1	I-AdverseReaction
activity	ERWINAZE.xml:S2:2243:8	I-AdverseReaction
,	ERWINAZE.xml:S2:2251:1	O
protein	ERWINAZE.xml:S2:2253:7	I-AdverseReaction
S	ERWINAZE.xml:S2:2261:1	I-AdverseReaction
activity	ERWINAZE.xml:S2:2263:8	I-AdverseReaction
,	ERWINAZE.xml:S2:2271:1	O
and	ERWINAZE.xml:S2:2273:3	O
anti	ERWINAZE.xml:S2:2277:4	I-AdverseReaction
-	ERWINAZE.xml:S2:2281:1	I-AdverseReaction
thrombin	ERWINAZE.xml:S2:2282:8	I-AdverseReaction
III	ERWINAZE.xml:S2:2291:3	I-AdverseReaction
.	ERWINAZE.xml:S2:2294:1	O

Discontinue	ERWINAZE.xml:S2:2296:11	O
ERWINAZE	ERWINAZE.xml:S2:2308:8	O
for	ERWINAZE.xml:S2:2317:3	O
a	ERWINAZE.xml:S2:2321:1	O
thrombotic	ERWINAZE.xml:S2:2323:10	O
or	ERWINAZE.xml:S2:2334:2	O
hemorrhagic	ERWINAZE.xml:S2:2337:11	O
event	ERWINAZE.xml:S2:2349:5	O
until	ERWINAZE.xml:S2:2355:5	O
symptoms	ERWINAZE.xml:S2:2361:8	O
resolve	ERWINAZE.xml:S2:2370:7	O
;	ERWINAZE.xml:S2:2377:1	O
after	ERWINAZE.xml:S2:2379:5	O
resolution	ERWINAZE.xml:S2:2385:10	O
,	ERWINAZE.xml:S2:2395:1	O
treatment	ERWINAZE.xml:S2:2397:9	O
with	ERWINAZE.xml:S2:2407:4	O
ERWINAZE	ERWINAZE.xml:S2:2412:8	O
may	ERWINAZE.xml:S2:2421:3	O
be	ERWINAZE.xml:S2:2425:2	O
resumed	ERWINAZE.xml:S2:2428:7	O
.	ERWINAZE.xml:S2:2435:1	O
